SCHEMBL5630581

SCHEMBL5630581

Cc1ccccc1Cn1c(CN2CCCN(Cc3ccc4c(c3)OCO4)CC2)nc2ccccc21

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 4/20 0.51
▸ CYP2D6 P10635 4/20 0.51
▸ CYP2C9 P11712 4/20 0.51
▸ CYP2C19 P33261 4/20 0.51
▸ MEN1 O00255 4/20 0.51
▸ KMT2A Q03164 4/20 0.51
▸ CYP3A4 P08684 3/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ NPSR1 Q6W5P4 2/20 0.51
▸ HIF1A Q16665 2/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ NR1I2 O75469 1/20 0.50
▸ ABCB11 O95342 1/20 0.50
▸ LMNA P02545 1/20 0.50
▸ ESR1 P03372 1/20 0.50
▸ PGR P06401 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ TSHR P16473 1/20 0.50
▸ ADRA2B P18089 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5628684 0.92 TSHR (0.54) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5627019 0.92 ALDH1A1 (0.49) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5626961 0.91 CYP1A2 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5629504 0.89 KDM4E (0.54) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5627119 0.89 CYP1A2 (0.50) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5626987 0.89 ALDH1A1 (0.53) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5629907 0.89 ALDH1A1 (0.55) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5626941 0.88 CYP1A2 (0.66) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL5628780 0.88 LMNA (0.53) CYP1A2CYP2D6CYP2C9CYP2C19MEN1
SCHEMBL7087808 0.87 CYP1A2 (0.64) CYP1A2CYP2D6CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160879-B2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues NEUROGEN CORPORATION (US) 2007-01-09 — — US claimed
EP-1465635-A4 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES NEUROGEN CORP (US) 2005-04-13 — — EP claimed
EP-1465635-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES NEUROGEN CORPORATION (US) 2004-10-13 — — EP claimed
US-20030229074-A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues NEUROGEN CORPORATION 2003-12-11 — — US claimed
WO-2003060475-A2 MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED 2-(4-BENZYL-PIPERAZIN-1-YLMETHYL)- AND 2-(4-BENZYL-DIAZEPAN-1-YLMETHYL)-1H-BENZOIMIDAZOLE ANALOGUES NEUROGEN CORPORATION (US) 2003-07-24 — — WO claimed
US-7160879-B2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues NEUROGEN CORPORATION (US) 2007-01-09 — — US disclosed
US-7160879-B2 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues NEUROGEN CORPORATION (US) 2007-01-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229074-A1 Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues MCHR1, MCHR2, MC1R CYP1A2 582/4885CYP2D6 1264/4885CYP2C9 1792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback